NASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $37.57 +0.46 (+1.24%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Royalty Pharma Stock (NASDAQ:RPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Royalty Pharma alerts:Sign Up Key Stats Today's Range$37.22▼$37.7450-Day Range$32.45▼$37.2752-Week Range$24.05▼$37.74Volume654,084 shsAverage Volume4.41 million shsMarket Capitalization$21.12 billionP/E Ratio20.28Dividend Yield2.34%Price Target$49.00Consensus RatingBuy Company Overview Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Read More Royalty Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreRPRX MarketRank™: Royalty Pharma scored higher than 98% of companies evaluated by MarketBeat, and ranked 27th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Royalty Pharma's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.24% Earnings GrowthEarnings for Royalty Pharma are expected to grow by 8.24% in the coming year, from $4.49 to $4.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 20.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 20.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.14.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 2.47. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Royalty Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.04% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 1.06%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.39%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has been increasing its dividend for 5 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 47.57%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 18.11% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. Sustainability and ESG3.7 / 5Environmental Score-2.25 Percentage of Shares Shorted5.04% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 1.06%, indicating that investor sentiment is improving. News and Social Media3.6 / 5News Sentiment1.42 News SentimentRoyalty Pharma has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Royalty Pharma this week, compared to 9 articles on an average week.Search InterestOnly 13 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat Follows10 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders18.90% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RPRX Stock News Headlines2 Reasons to Watch RPRX and 1 to Stay CautiousJuly 30, 2025 | msn.comIf EPS Growth Is Important To You, Royalty Pharma (NASDAQ:RPRX) Presents An OpportunityJuly 26, 2025 | finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 4 at 2:00 AM | Brownstone Research (Ad)Royalty Pharma plc (RPRX) Stock Dividend Growth Grade & History ...July 24, 2025 | seekingalpha.comWinners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals StocksJuly 24, 2025 | msn.comRoyalty Pharma PLC Announces Third Quarter 2025 Dividend Payment | RPRX stock newsJuly 18, 2025 | gurufocus.comRoyalty Pharma Declares Third Quarter 2025 DividendJuly 18, 2025 | globenewswire.comRoyalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of DirectorsJuly 17, 2025 | finance.yahoo.comSee More Headlines RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $25.51 at the beginning of 2025. Since then, RPRX stock has increased by 47.1% and is now trading at $37.53. How were Royalty Pharma's earnings last quarter? Royalty Pharma PLC (NASDAQ:RPRX) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The biopharmaceutical company earned $839 million during the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 48.23% and a trailing twelve-month return on equity of 24.71%. Read the conference call transcript. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an IPO on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Top institutional shareholders of Royalty Pharma include Wedge Capital Management L L P NC (0.22%), Sumitomo Mitsui Trust Group Inc. (0.16%), Robeco Institutional Asset Management B.V. (0.14%) and DekaBank Deutsche Girozentrale (0.13%). Insiders that own company stock include 1978 Sicaf Sif SA Gg, 1978 Sicaf Sif SA - Gg St Gg, Mario Germano Giuliani, Avara Management Ltd, Terrance P Coyne, James F Reddoch, Pablo G Legorreta, George W Lloyd, Marshall Urist and Rory B Riggs. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Bristol Myers Squibb (BMY), Chevron (CVX), McKesson (MCK), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/08/2025Record date for 6/10 Dividend5/16/2025Ex-Dividend for 6/10 Dividend5/16/2025Dividend Payable6/10/2025Today8/04/2025Next Earnings (Estimated)8/06/2025Record date for 9/10 Dividend8/15/2025Ex-Dividend for 9/10 Dividend8/15/2025Dividend Payable9/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CIK1802768 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees80Year Founded1996Price Target and Rating Average Price Target for Royalty Pharma$49.00 High Price Target$54.00 Low Price Target$42.00 Potential Upside/Downside+32.0%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$1.85 Trailing P/E Ratio20.06 Forward P/E Ratio8.27 P/E Growth2.47Net Income$858.98 million Net Margins48.23% Pretax Margin78.11% Return on Equity24.71% Return on Assets13.87% Debt Debt-to-Equity Ratio0.68 Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual Sales$2.26 billion Price / Sales9.22 Cash Flow$4.19 per share Price / Cash Flow8.85 Book Value$17.56 per share Price / Book2.11Miscellaneous Outstanding Shares562,240,000Free Float455,977,000Market Cap$20.86 billion OptionableOptionable Beta0.55 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RPRX) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThis rock I’m holding could be worth trillionsA strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.